Iovance Biotherapeutics is trading 13.37% higher at $16.79 after announcing positive results from Phase 2 registrational cohorts of lifileucel in previously treated metastatic non-small cell lung cancer.
- The company announced the results at 7:00 p.m. ET.
- A webcast is scheduled for 8:30 a.m. ET on October 29 to discuss the data and precision-medicine opportunities.
- The announcement did not provide specific study-result figures.